Clinical trials have shown impressive results: people taking tirzepatide , alongside a reduced-calorie diet and increased physical activity, lost on average 15% to 22% of their body weight over about 72 weeks
Now that the FDA declared the semaglutide shortage over, and given pharmacies a deadline to stop producing it, compounded semaglutide many not be widely available after May 2025
This comparison examines the clinical data supporting each agent, including the landmark head-to-head trial, independent program data, cardiovascular outcomes, and practical considerations for treatment selection
Spiering BA, Kraemer WJ, Vingren JL, Hatfield DL, Fragala MS, Ho JY et al
Los medicamentos compuestos no son productos aprobados por la FDA